Sangamo Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Sangamo Therapeutics sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).

25 total trials 1 currently recruiting 18 completed early-phase tilt top decile by trial count

Sangamo Therapeutics: 25 sponsored US clinical trials, 1 recruiting.

Sangamo Therapeutics sponsors 25 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 18 completed. 0 of these trials are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetic Polyneuropathy, with 2 trials.

Top-decile sponsor footprint

Sangamo Therapeutics ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

18 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

25 total, page 1 of 1

RECRUITING Phase 1

Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)

NCT06980948
ACTIVE NOT RECRUITING

Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.

NCT05145062
ACTIVE NOT RECRUITING

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

NCT04628871
COMPLETED Phase 1

Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)

NCT04046224
COMPLETED Phase 1

A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

NCT03653247
COMPLETED Phase 1

A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)

NCT03432364
TERMINATED Phase 1

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I

NCT02702115
TERMINATED Phase 1

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

NCT03041324
TERMINATED Phase 1

Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

NCT02695160
COMPLETED Phase 1

Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART

NCT02225665
COMPLETED Phase 1

Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T

NCT01543152
TERMINATED

Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T

NCT04201782
COMPLETED Phase 1

Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects

NCT01252641
COMPLETED Phase 1

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

NCT01044654
COMPLETED Phase 2

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT01079325
COMPLETED Phase 1

Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

NCT00985517
COMPLETED Phase 2

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00876863
COMPLETED Phase 2

Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT00748501
COMPLETED Phase 2

Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509

NCT00665145
COMPLETED Phase 2

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT00476931
COMPLETED Phase 2

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT00406458
COMPLETED Phase 2

Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease

NCT00400634
COMPLETED Phase 1

Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease

NCT00252850
COMPLETED Phase 1

Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy

NCT00110500
COMPLETED Phase 1

CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00087789

Phase Distribution

PhaseTrial count
Phase 1 15
Phase 2 7

Therapeutic Areas

Diabetic Polyneuropathy 2
Diabetes Mellitus, Type 1 2
Diabetes Mellitus, Type 2 2
Blood and Lymphatic Diseases 1
Transfusion-dependent Beta-Thalassemia 1
Chronic Neuropathic Pain 1
Idiopathic Parkinson´s Disease 1
Alzheimers Disease 1
Hemophilia B 1
HIV Infections 1

What is open in the Sangamo Therapeutics pipeline

1 recruiting of 25 indexed (4% open); 18 completed (72%).

Phase mix: 0 late (III/IV) vs 22 early (I/II) (early-phase heavy).

Top condition: Diabetic Polyneuropathy (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Sangamo Therapeutics: open-pipeline peers nationwide

Peers matched on 25 registered trials and 4% open enrollment, not the therapeutic-area sidebar.

Sangamo Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 2030405060 0%5%10%15% Total trials Recruiting share Sangamo TherapeuticsArcus BiosciencesArcutis BiotherapeuticsArdelyxDrexel University College of MedicineFisher and Paykel HealthcareMesoblastResMedMedtronicNeuro
Sangamo Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Sangamo Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 25 trials (± recruiting share)

Sponsors near 4% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Sangamo Therapeutics page

25 registered trials is a research-attention snapshot, not an endorsement of Sangamo Therapeutics or any single study.

  • 1 of Sangamo Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Diabetic Polyneuropathy is the condition Sangamo Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetic Polyneuropathy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Sangamo Therapeutics pipeline card: 25 registered trials from official public datasets.Report a data error.